Hana Safah MD

Oncology•Baton Rouge, LA

Professor, Medicine, Tulane University School of Medicine

Join to View Full Profile

7777 Hennessy BlvdSte 7000Baton Rouge, LA 70808
Phone+1 225-757-0343
Fax+1 225-757-8354

Education & Training

Tulane UniversityResidency, Internal Medicine, 1994 - 1995
University of FloridaFellowship, Hematology and Medical Oncology, 1991 - 1994
Greater Baltimore Medical CenterResidency, Internal Medicine, 1989 - 1991
American University of Beirut Faculty of MedicineClass of 1987

Certifications & Licensure

LA State Medical License 1994 - 2025
FL State Medical License 1992 - 1998
MD State Medical License 1991 - 1993
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2009 Dec 10
Completed
Phase 2
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
Terminated
Phase 2
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
ACTIVE_NOT_RECRUITING
PHASE3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
COMPLETED
PHASE2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
ACTIVE_NOT_RECRUITING
PHASE3
Convalescent Plasma to Stem Coronavirus (CSSC-001) Start of enrollment: 2020 Jun 10
Completed
Phase 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Start of enrollment: 2020 Jun 03
Completed
Phase 2
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 26
COMPLETED
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.
John Mascarenhas, Prithviraj Bose, Christopher Hillis, Abdulraheem Yacoub, Firas El Chaer
Acta Haematologica. 2025-03-05
Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.
Moayed Ibrahim, Catherine Murphree, Kirtesh Patel, Matthew Mastrodomenico, Nakhle S Saba
Cancer Reports. 2024-09-01
1 citations
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Firas M Safa, Terri Rasmussen, Lorena Fontan, Min Xia, Ari Melnick
Haematologica. 2024-05-01

Abstracts/Posters

Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-...
Hana Safah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia
Hana Safah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Hana Safah MD

Dr. Safah is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.